The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway

Cancer Letters

Volumn 371, Issue 2, 2016, Pages 314-325

  Jiang, Weiliang ^a   Zhao, Senlin ^a   Jiang, Xiaohua ^b   Zhang, Erquan ^c   Hu, Guoyong ^a   Hu, Bin ^a   Zheng, Ping ^b   Xiao, Junhua ^b   Lu, Zhanjun ^a   Lu, Yingying ^a   Ni, Jianbo ^a   Chen, Congying ^a   Wang, Xingpeng ^a   Yang, Lijuan ^a   Wan, Rong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES   (China)

Author keywords

Apoptosis; Bmal1; Cell cycle arrest; Circadian clock; P53; Pancreatic cancer

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR ARNTL; TRANSCRIPTOME; ARNTL PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BMAL1 GENE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVATION; GENE FUNCTION; GENE INTERACTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; RNA ANALYSIS; RNA SEQUENCE; TRANSCRIPTION INITIATION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; ANIMAL; BINDING SITE; CELL MOTION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; APOPTOSIS; ARNTL TRANSCRIPTION FACTORS; BINDING SITES; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME; TRANSFECTION; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84962032986     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.12.002     Document Type: Article

References (51)

1. Bass J., Takahashi J.S. Circadian integration of metabolism and energetics. Science 2010, 330:1349-1354.
2. Zhang E.E., Kay S.A. Clocks not winding down: unravelling circadian networks. Nat. Rev. Mol. Cell Biol 2010, 11:764-776.
3. Robinson I., Reddy A.B. Molecular mechanisms of the circadian clockwork in mammals. FEBS Lett 2014, 588:2477-2483.
4. Chen L., Yang G. Recent advances in circadian rhythms in cardiovascular system. Front. Pharmacol 2015, 6:71.
5. Gamble K.L., Berry R., Frank S.J., Young M.E. Circadian clock control of endocrine factors. Nat. Rev. Endocrinol 2014, 10:466-475.
6. Savvidis C., Koutsilieris M. Circadian rhythm disruption in cancer biology. Mol. Med 2012, 18:1249-1260.
7. Bunger M.K., Wilsbacher L.D., Moran S.M., Clendenin C., Radcliffe L.A., Hogenesch J.B., et al. Mop3 is an essential component of the master circadian pacemaker in mammals. Cell 2000, 103:1009-1017.
8. Razorenova O.V. Brain and muscle ARNT-like protein BMAL1 regulates ROS homeostasis and senescence: a possible link to hypoxia-inducible factor-mediated pathway. Cell Cycle 2012, 11:213-214.
9. Hatanaka F., Matsubara C., Myung J., Yoritaka T., Kamimura N., Tsutsumi S., et al. Genome-wide profiling of the core clock protein BMAL1 targets reveals a strict relationship with metabolism. Mol. Cell. Biol 2010, 30:5636-5648.
10. Khapre R.V., Samsa W.E., Kondratov R.V. Circadian regulation of cell cycle: molecular connections between aging and the circadian clock. Ann. Med 2010, 42:404-415.
11. Kondratov R.V., Kondratova A.A., Gorbacheva V.Y., Vykhovanets O.V., Antoch M.P. Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock. Genes Dev 2006, 20:1868-1873.
12. Izumi H., Wang K., Morimoto Y., Sasaguri Y., Kohno K. Circadian disruption and cancer risk: a new concept of stromal niche (review). Int. J. Oncol 2014, 44:364-370.
13. Gery S., Koeffler H.P. The role of circadian regulation in cancer. Cold Spring Harb. Symp. Quant. Biol 2007, 72:459-464.
14. Haus E.L., Smolensky M.H. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med. Rev 2013, 17:273-284.
15. Brudnowska J., Peplonska B. Night shift work and cancer risk: a literature review. Med. Pr 2011, 62:323-338.
16. Zeng Z.L., Luo H.Y., Yang J., Wu W.J., Chen D.L., Huang P., et al. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clin. Cancer Res 2014, 20:1042-1052.
17. Yeh C.M., Shay J., Zeng T.C., Chou J.L., Huang T.H., Lai H.C., et al. Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer. Int. J. Oncol 2014, 45:2101-2107.
18. Taniguchi H., Fernandez A.F., Setien F., Ropero S., Ballestar E., Villanueva A., et al. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res 2009, 69:8447-8454.
19. Elshazley M., Sato M., Hase T., Yamashita R., Yoshida K., Toyokuni S., et al. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma. Int. J. Cancer 2012, 131:2820-2831.
20. Delezie J., Challet E. Interactions between metabolism and circadian clocks: reciprocal disturbances. Ann. N. Y. Acad. Sci 2011, 1243:30-46.
21. Sadacca L.A., Lamia K.A., de Lemos A.S., Blum B., Weitz C.J. An intrinsic circadian clock of the pancreas is required for normal insulin release and glucose homeostasis in mice. Diabetologia 2011, 54:120-124.
22. Pogue-Geile K.L., Lyons-Weiler J., Whitcomb D.C. Molecular overlap of fly circadian rhythms and human pancreatic cancer. Cancer Lett 2006, 243:55-57.
23. Suzuki T., Sato F., Kondo J., Liu Y., Kusumi T., Fujimoto K., et al. Period is involved in the proliferation of human pancreatic MIA-PaCa2 cancer cells by TNF-alpha. Biomed. Res 2008, 29:99-103.
24. Oda A., Katayose Y., Yabuuchi S., Yamamoto K., Mizuma M., Shirasou S., et al. Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin. Anticancer Res 2009, 29:1201-1209.
25. Relles D., Sendecki J., Chipitsyna G., Hyslop T., Yeo C.J., Arafat H.A. Circadian gene expression and clinicopathologic correlates in pancreatic cancer. J. Gastrointest. Surg 2013, 17:443-450.
26. Tavano F., Pazienza V., Fontana A., Burbaci F.P., Panebianco C., Saracino C., et al. SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: effect of starvation. Chronobiol. Int 2015, 32:497-512.
27. Guo B., Chatterjee S., Li L., Kim J.M., Lee J., Yechoor V.K., et al. The clock gene, brain and muscle Arnt-like 1, regulates adipogenesis via Wnt signaling pathway. FASEB J. 2012, 26:3453-3463.
28. Batchu R.B., Gruzdyn O.V., Qazi A.M., Kaur J., Mahmud E.M., Weaver D.W., et al. Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer. Surgery 2015, 158:981-987.
29. Xu Q., Li P., Chen X., Zong L., Jiang Z., Nan L., et al. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Oncotarget 2015, 6:14153-14164.
30. Huang N., Chelliah Y., Shan Y., Taylor C.A., Yoo S.H., Partch C., et al. Crystal structure of the heterodimeric CLOCK:BMAL1 transcriptional activator complex. Science 2012, 337:189-194.
31. Mullenders J., Fabius A.W., Madiredjo M., Bernards R., Beijersbergen R.L. A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS ONE 2009, 4:e4798.
32. Khapre R.V., Kondratova A.A., Susova O., Kondratov R.V. Circadian clock protein BMAL1 regulates cellular senescence in vivo. Cell Cycle 2011, 10:4162-4169.
33. Jung C.H., Kim E.M., Park J.K., Hwang S.G., Moon S.K., Kim W.J., et al. Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol. Rep 2013, 29:2109-2113.
34. Li B., Gao Y., Rankin G.O., Rojanasakul Y., Cutler S.J., Tu Y., et al. Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells. Cancer Lett 2015, 356:418-433.
35. Delbridge A.R., Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 2015, 22:1071-1080.
36. Sullivan K.D., Gallant-Behm C.L., Henry R.E., Fraikin J.L., Espinosa J.M. The p53 circuit board. Biochim. Biophys. Acta 1825, 2012:229-244.
37. Sato F., Nagata C., Liu Y., Suzuki T., Kondo J., Morohashi S., et al. PERIOD1 is an anti-apoptotic factor in human pancreatic and hepatic cancer cells. J. Biochem 2009, 146:833-838.
38. Kettner N.M., Katchy C.A., Fu L. Circadian gene variants in cancer. Ann. Med 2014, 46:208-220.
39. Reinhardt H.C., Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 2012, 28:128-136.
40. Gurpinar E., Vousden K.H. Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation. Trends Cell Biol 2015, 25:486-495.
41. Chipuk J.E., Fisher J.C., Dillon C.P., Kriwacki R.W., Kuwana T., Green D.R. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:20327-20332.
42. Hunt T., Sassone-Corsi P. Riding tandem: circadian clocks and the cell cycle. Cell 2007, 129:461-464.
43. Bieler J., Cannavo R., Gustafson K., Gobet C., Gatfield D., Naef F. Robust synchronization of coupled circadian and cell cycle oscillators in single mammalian cells. Mol. Syst. Biol 2014, 10:739.
44. Feillet C., Krusche P., Tamanini F., Janssens R.C., Downey M.J., Martin P., et al. Phase locking and multiple oscillating attractors for the coupled mammalian clock and cell cycle. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:9828-9833.
45. Mazzoccoli G., Pazienza V., Vinciguerra M. Clock genes and clock-controlled genes in the regulation of metabolic rhythms. Chronobiol. Int 2012, 29:227-251.
46. Feillet C., van der Horst G.T., Levi F., Rand D.A., Delaunay F. Coupling between the circadian clock and cell cycle oscillators: implication for healthy cells and malignant growth. Front. Neurol 2015, 6:96.
47. Kreis N.N., Louwen F., Yuan J. Less understood issues: p21(Cip1) in mitosis and its therapeutic potential. Oncogene 2015, 34:1758-1767.
48. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
49. O'Brien V., Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 2006, 27:682-692.
50. Ujiki M.B., Ding X.Z., Salabat M.R., Bentrem D.J., Golkar L., Milam B., et al. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer 2006, 5:76.
51. Zhou X., Zheng M., Chen F., Zhu Y., Yong W., Lin H., et al. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. Anat. rec 2009, 292:1122-1127.